1 / 30

Investigational New Drug Application 21 CFR Part 312

A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International gclasby@promedica-intl.com 714-799-1617 x 25. Investigational New Drug Application 21 CFR Part 312. IND Application About the Regulation.

dalton-beck
Download Presentation

Investigational New Drug Application 21 CFR Part 312

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International gclasby@promedica-intl.com 714-799-1617 x 25 Investigational New Drug Application21 CFR Part 312

  2. IND ApplicationAbout the Regulation • Provides procedures for use of investigational new drugs • Exempts products from premarketing approval requirements: • Registration, listing, interstate distribution • Labeling • GMPs • Applies to most studies to determine drug safety & effectiveness

  3. When IND Application is Not RequiredClinical Study Situations • Drug legally marketed for indicated use • Study not intended to support new indication or significant labeling change • Study not intended to support significant change in advertising • Study doesn’t involve change in route of admin, dosage, or use that significantly increases patient risks • IVD biological for confirmatory diagnostic procedure • Intended for tests of in vitro or lab research animals • Placebo products

  4. “Treatment” INDWhen Used • Drug intended to treat or diagnose serious or life-threatening condition • No satisfactory alternative available • Controlled clinical trials in progress under IND • Or when trials completed & FDA review of request to market is pending • Sponsor actively pursuing device marketing approval with FDA

  5. “Emergency Use” INDWhen Used • Need FDA authorization to use experimental drug in an emergency situation that does not allow time for submission of an IND in accordance with  21 CFR Part 312 • May be used for patients ineligible per existing study protocol(s), or if approved study protocol does not exist

  6. IND ApplicationProduct Labeling Requirements • Immediate package must be labeled: • “Caution: New Drug – Limited by Federal (or United States) law to investigational use” • No false or misleading statements • No representation that drug is safe or effective for indicated use

  7. IND ApplicationPromotion & Charging for Investigational Drugs • No representation that drug is safe or effective for indicated use • No commercial distribution or test marketing • No prolongation of study • Prior written approval from FDA required to “charge” for drug, unless being used under “treatment” IND

  8. IND ApplicationClinical Study Phases • Phase 1 – first time in human • Small number of healthy volunteers • Closely monitored – focus on safety • Phase 2 – controlled studies to evaluate effectiveness • Small number of subjects with condition to be treated • Closely monitored – focus on efficacy (& safety) • Phase 3 – expanded controlled & uncontrolled studies • Large number of subjects with condition to be treated • Focus on efficacy (& safety)

  9. IND Application ContentsAdministrative Details • Sponsor responsibility • Submit original & 2 copies of application • FDA notifies Sponsor in writing of date application is received • IND in effect 30 days after FDA receipt of application, unless FDA notifies Sponsor otherwise

  10. IND Review/ApprovalFDA’s Considerations • Subject safety & welfare • Rendered  30 days of FDA receipt • Only disapproval or early approval is rendered in writing • Clinical hold may be ordered if: • Sponsor fails to comply with applicable regulations • Sponsor is non-responsive to requests for add’l info • Subject risks outweigh benefits • Unreasonable to proceed due to inadequacy of investigational plan, manufacturing or monitoring

  11. Clinical HoldsTo Delay/Suspend A Study • Phase I clinical holds • Subject safety concerns • Phase II & III clinical holds • Concerns about safety or efficacy • Treatment IND clinical holds • Alternative treatment drug now commercially available • Sponsor not diligently pursuing marketing approval • Administrative oversights by Sponsor

  12. IND Application ContentsAn Overview • Cover sheet/application form (Form FDA-1571) • Table of contents • Introductory statement • General investigational plan • Investigator brochure • Protocol(s) • Chemistry, manufacturing & control info

  13. IND Application ContentsAn Overview • Pharmacology & toxicology info • Previous human experience with drug • Add’l info as required: • Drug dependence/abuse potential • Radioactive drugs • Pediatric studies • Add’l info as requested by FDA

  14. IND Application ContentsApplication Form - FDA 1571 • Required for initial IND & all subsequent submissions • Provides basic info about Sponsor & submission contents • Must be signed & dated • Obligates Sponsor to comply with laws & regs

  15. IND Application ContentsIntroductory Statement • Drug name, structure, pharmacological class, development history, foreign testing

  16. IND Application ContentsGeneral Investigational Plan • Summary of studies anticipated in first year • Study rationale

  17. IND Application ContentsInvestigator Brochure • Package insert • Early versions contain more pre-clinical data • Later versions more heavily weighted with clinical data

  18. IND Application ContentsProtocol(s) • Must include at least the initial protocol • Phase I – protocol outline: • No. subjects planned • Eligibility requirements • Dosing • Safety assessments • Phase II & III – detailed protocols

  19. IND Application ContentsChemistry, Manufacturing & Controls • Manufacturing process • Raw materials & finished product testing • May refer to drug master file or previous application

  20. IND Application ContentsPharmacology & Toxicology • Non-clinical study summaries of pharmacological & toxicological effects

  21. IND Application ContentsPrevious Human Experience • Foreign trials • Data from other INDs, NDAs

  22. IND Application ContentsAdditional Info • Other relevant info • Minutes of FDA meetings • Copies of referenced materials • Address issues re: possible drug abuse, dependence, radioactivity, etc.

  23. IND AmendmentsNecessary When: • New protocol introduced • Changes made to protocol that may affect: • Scientific soundness of study • Rights, safety or welfare of study subjects • Addition of new study investigators (FDA Form 1572) • New/revised information not related to protocol • New pharmacology, toxicology, chemistry, clinical info • Discontinuance of a study

  24. IND Safety Reports FDA Form 3500A • Any unexpected, serious adverse experience associated with drug use – 15 calendar days • Any finding from animal studies suggesting significant risk for human subjects – 15 calendar days • Any unexpected fatal or life-threatening experience associated with drug use – 7 calendar days

  25. IND Annual ReportsWhen Required • Due within 60 days of IND anniversary • Individual study information • Summary information for all studies, including: • Summary of safety results & significant changes in product manufacturing, pre-clinical study status • General investigational plan for upcoming year • Any Investigator Brochure revisions • Significant Ph I protocol modifications • Significant foreign marketing developments during prior year • Log of outstanding business

  26. IND Review/ApprovalFDA Meetings • Pre-IND Submission • Facilitates planning for IND • End of Phase II • Facilitates planning for later studies • Pre-NDA or Pre-BLA • Facilitates preparation & review of NDA or BLA

  27. Sponsors & InvestigatorsResponsibilities • Similar to 21 CFR 812

  28. IRBResponsibilities • As identified in 21 CFR 50, 56

  29. IND RegulationReference Documents & Links (www.fda.gov/cder) • CDER Guidance: IND Application Process (interactive session) http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm

  30. IND RegulationReference Documents & Links (www.fda.gov/cder) • FDA Guidance for Financial Disclosure by Clinical Investigators • FDA Guidance for IRBs & Clinical Investigators • FDA Guidance for Monitoring Clinical Investigations • FDA/ORA Compliance Program Guidance for Bioresearch Monitoring of Clinical Investigations

More Related